Patología comparativa de la aterosclerosis en primates no humanos

Una revisión histórico-crítica de la progresión, estabilización, regresión y la dinámica de placa y lípidos (1950–1995)

Resumen ejecutivo

El paradigma de ateroesclerosis a mediados del siglo XX pasó de ver la condición como una consecuencia inevitable y progresiva del envejecimiento a entenderla como una enfermedad inflamatoria dinámica impulsada por lípidos en la que la regresión sustancial y la estabilización son biológicamente posibles bajo algunas condiciones experimentales. Gran parte de la evidencia fundamental de este cambio se estableció a través de modelos de primates no humanos desarrollados entre 1950 y finales de la década de 1980. En comparación con muchos modelos de roedores y conejos de uso común, determinados primates no humanos poseen lipoproteína metabolismo, apolipoproteína B (ApoB) biología y anatomía arterial coronaria que se aproximan más a las características importantes de la aterosclerosis humana. Esta revisión científica de base histórica examina la progresión, estabilización y regresión de la aterosclerosis inducida por la dieta en varias especies de primates, incluidas macacos rhesus, macacos cangrejeros, monos verdes africanos, babuinos y monos ardilla.

Estas investigaciones históricas demuestran que determinados primates no humanos desarrollan coronarias complejas similares a las humanas placas con la participación de cápsulas fibrosas, núcleos necróticos ricos en lípidos, la remodelación de la matriz extracelular y calcificación. Espontáneo infarto de miocardio también se informó, aunque con mucha menos frecuencia. Además, los análisis seriados y post mortem proporcionan evidencia experimental de que la marcada y sostenida reversión de hipercolesterolemia, logrado mediante una modificación importante de la dieta y, en algunos experimentos, intervenciones adicionales para reducir los lípidos, puede inducir regresión de la placa. A lo largo de estos estudios, la regresión y la estabilización se caracterizaron por el agotamiento de las reservas intracelulares y extracelulares de ésteres de colesterol en la placa y por la reducción de los componentes celulares ricos en lípidos y necróticos; los estudios que evaluaron directamente la función vascular también demostraron la recuperación de respuestas vasomotoras endoteliales. Sin embargo, con frecuencia persisten componentes de la matriz densamente fibróticos y macrocalcificados, lo que limita la normalización anatómica completa. Al evaluar los parámetros dietéticos, cinéticos y metodológicos de estos estudios históricos, este informe proporciona un puente transnacional hacia los estudios modernos en humanos, delineando tanto la relevancia traslacional como los límites biológicos de la terapia de regresión de la placa.

Evolución histórica y cronología

El estudio sistemático de la aterosclerosis en primates no humanos evolucionó a través de distintas fases experimentales, siguiendo los avances en bioquímica analítica, histopatología y tecnologías de imagen. La tabla a continuación describe los hitos de esta investigación, detallando cómo los investigadores avanzaron desde la observación temprana de depósitos lipídicos vasculares hasta evaluaciones funcionales y de alta resolución de la biología de la placa.

Punto	Enfoque experimental y avances metodológicos	Centros de investigación pioneros clave	Contribuciones científicas históricas
década de 1950	Inducción de hipercolesterolemia y tinción de lípidos vasculares en primates del Nuevo Mundo; exploración de deficiencias nutricionales.	Escuela de Salud Pública de Harvard; Escuela de Medicina Bowman Gray.	Entre las inducciones experimentales tempranas de hipercolesterolemia en monos del Nuevo Mundo; caracterización de la susceptibilidad vascular del cebú y el rhesus.
década de 1960	Enfócate en la coronaria arteria patología e historia natural; informes tempranos de infarto de miocardio espontáneo en monos hiperlipidémicos.	Universidad Northwestern; Centro Regional de Investigación de Primates de Oregón.	Taylor y col. documentan un infarto de miocardio fatal inducido por la dieta en un macaco rhesus [1]. El estudio de Maruffo y Portman sobre los cambios coronarios tempranos en monos ardilla [2].
década de 1970	Evidencia morfométrica de regresión coronaria avanzada; mapeo detallado de las fases lipídicas de la placa y cambios en la matriz.	Universidad de Iowa; Universidad de Chicago; Centro Médico de LSU.	Armstrong y otros proporcionan evidencia morfométrica temprana de arteriopatía coronaria avanzada ateroma regresión en macacos rhesus3]. Vesselinovitch y Wissler evalúan dietas bajas en grasas combinadas con un agente farmacológico reductor de lípidos (W-1372) [4].
década de 1980	Estudios cinéticos de regresión a largo plazo y de varios años; análisis físico-químicos de las transiciones de fase lipídica; modelado epidemiológico de HDL.	Escuela de Medicina Bowman Gray; Universidad de Boston; Fundación Suroeste para la Investigación Biomédica.	Clarkson y col. compararon la regresión a largo plazo con niveles de colesterol total plasmático cercanos a 200 frente a 300 mg/dl [5]. Small et al. caracterizan el carácter transitorio cristalización de placa a los 6 meses de regresión6].
década de 1990	Integración de histomorfometría con angiografía cuantitativa, reactividad endotelial y remodelación vascular compensatoria.	Escuela de Medicina Bowman Gray; Centro Médico de la LSU.	Williams y col. informan aproximadamente duplicadas la arteria coronaria y lumen áreas transversales, coherentes con favorable remodelación exterior, junto con una mejorada función vasomotora [7]. El equipo de LSU completa un estudio de varios años sobre placas en rhesus [8].

Modelos de primates: patobiología específica de la especie y perfiles metabólicos

La selección de una especie de primate no humano en la investigación de la aterosclerosis está guiada por consideraciones genéticas, metabólicas y anatómicas. Elegir el modelo correcto es fundamental, ya que las diferencias entre especies en el transporte de lipoproteínas y la susceptibilidad arterial afectan directamente la traslación de los resultados experimentales a la práctica clínica humana.

Macacos Rhesus (Macaca mulatta)

Los monos rhesus han sido históricamente el modelo de primate más utilizado para la investigación de la aterosclerosis. Bajo un desafío dietético aterogénico, los monos rhesus susceptibles pueden pasar de perfiles de lipoproteínas basales relativamente dominantes en HDL hacia un enriquecimiento marcado de lipoproteínas que contienen ApoB, produciendo un perfil plasmático que se asemeja a características importantes de la hiperlipoproteinemia humana. Los monos rhesus son altamente sensibles a colesterol dietético y grasa saturada. Desarrollan de manera confiable placas coronarias avanzadas, concéntricas y excéntricas que progresan hacia núcleo necrótico formación, descomposición celular, hemorragia intraplaca, y calcificación. Se ha documentado un infarto de miocardio espontáneo, aunque sigue siendo poco común, en estudios a largo plazo con monos rhesus, lo que convierte a esta especie en un modelo líder para la clínica enfermedad de las arterias coronarias.

Macacos cangrejeros (Macaca fascicularis)

Los macacos cangrejeros son altamente sensibles a la dieta colesterol, lo que los convierte en un modelo excelente para un rápido lesión inducción. Son propensos a desarrollar lesiones arteriales coronarias avanzadas con una alta proporción de tejido conectivo, incluido el colágeno, elastina, y glicosaminoglucanos, así como una calcificación densa. Los monos cynomolgus también exhiben un alto grado de reactividad al estrés psicosocial. El estrés psicosocial y el estatus social se han asociado experimentalmente con diferencias en las arterias coronarias aterogénesis en esta especie, reportada particularmente en machos dominantes y en hembras socialmente subordinadas, con la activación del sistema nervioso simpático y la hipercortisolemia propuestas como mecanismos neuroendocrinos que contribuyen más allá de las concentraciones de lípidos circundantes. Esto los convierte en un modelo valioso para examinar la relación entre el estrés psicosocial y la enfermedad vascular.

Monos verdes africanos (Chlorocebus aethiops)

Los monos verdes africanos (vervets) poseen un metabolismo de las lipoproteínas que es altamente sensible a la composición específica de ácidos grasos de la dieta. Cuando se alimentan con ácidos grasos monoinsaturados frente a saturados o grasas poliinsaturadas, muestran claras variaciones en LDL el tamaño y la densidad son relevantes para las respuestas de los lípidos en la dieta humana. Sus lesiones coronarias se desarrollan más lentamente que las de los macacos, pero comparten características morfológicas importantes con las placas humanas, incluida la distribución de las lesiones y la presencia de ambas células de músculo liso y macrófago células espumosas, aunque persisten las diferencias específicas de cada especie en la composición celular y el metabolismo de los lípidos.

Babuinos (Papio hamadryas/sp.)

Los babuinos son primates del Viejo Mundo grandes y genéticamente heterogéneos, ampliamente utilizados para estudiar los determinantes genéticos y ambientales del riesgo cardiovascular. Desarrollan naturalmente etapas tempranas de estrías grasas y placas fibrosas en ramificaciones arteriales predecibles, incluida la bifurcación ilíaca y la abdominal aorta. Su crecimiento, desarrollo y envejecimiento siguen un patrón generalizado de primates del Viejo Mundo, y exhiben variaciones similares a las humanas en las respuestas de lipoproteínas, presión arterial, y la distensibilidad vascular bajo un desafío dietético. Sin embargo, son relativamente resistentes a desarrollar una oclusión severa estenosis de la arteria coronaria o eventos isquémicos terminales dentro de los plazos experimentales estándar, lo que limita su utilidad para ensayos avanzados de regresión.

Monos ardilla (Saimiri sciureus)

Como primates pequeños del Nuevo Mundo, los monos ardilla ofrecen un modelo compacto para la investigación de la aterosclerosis. Desarrollan de forma natural lesiones aórticas y coronarias, y son muy sensibles a las manipulaciones de los lípidos en la dieta a corto plazo. El regreso a dietas bajas en colesterol en los monos ardilla puede reducir la carga de lípidos y células espumosas en las lesiones y detener la progresión de las lesiones tempranas; el grado de regresión anatómica demostrada cuantitativamente en la literatura inicial sobre el mono ardilla es menos certero. Sin embargo, su pequeño calibre vascular y las limitaciones de sus dimensiones físicas generales dificultan la angiografía seriada, la imagen intravascular y las mediciones del flujo hemodinámico regional.

Ventajas comparativas de los modelos de primates sobre los modelos no primates

Los primates no humanos ofrecen varias ventajas fisiológicas y estructurales sobre los modelos de mamíferos inferiores para abordar cuestiones sobre la enfermedad coronaria humana, aunque ninguna especie en particular es óptima para todos los propósitos y otros modelos (conejos, cerdos y ratones genéticamente modificados) pueden ser preferibles para cuestiones mecanicistas, intervencionistas o de imagen específicas:

• Distribución de lipoproteínas y CETP Actividad: Los ratones y ratas de laboratorio comunes transportan gran parte de su colesterol circulante en partículas de HDL y carecen de plasma apreciable éster de colesterilo transferencia proteína actividad de la (CETP). Estas características hacen que la hiperlipidemia espontánea de tipo humano y dominada por ApoB sea poco común en estas especies y a menudo requiera manipulación genética o dietética para modelar la aterosclerosis humana. Muchas especies de primates no humanos poseen actividad de CETP y, cuando se exponen a colesterol y grasas saturadas en la dieta, desarrollan aumentos marcados en las lipoproteínas que contienen ApoB y una distribución de lipoproteínas similar a la hipercolesterolemia humana. Sin embargo, las distribuciones basales de lipoproteínas varían sustancialmente según la especie, la colonia, la dieta, el sexo y la capacidad de respuesta individual, y varios primates son relativamente dominantes en HDL antes de la administración de colesterol.
• Anatomía arterial y hemodinámica: Los primates no humanos poseen una coronaria gruesa y de múltiples capas íntima con una lámina elástica interna bien definida y adventicia vasa vasorum, que comparte varias características importantes de la arquitectura vascular coronaria humana. Los conejos, por el contrario, son extremadamente sensibles al colesterol de la dieta y acumulan con facilidad células espumosas de macrófagos cargadas de lípidos (la respuesta de la “célula de Anitschkow”); bajo protocolos prolongados o modificados también pueden desarrollar lesiones fibrosas, necróticas y calcificadas más avanzadas. Sin embargo, su extrema sensibilidad al colesterol dietético, su metabolismo de lipoproteínas distintivo y la frecuente concentración de la enfermedad en la aorta en lugar de eventos coronarios espontáneos similares a los humanos limitan su traducción directa en relación con ciertos modelos de primates seleccionados.
• Cascadas inflamatorias y trombóticas: Los primates exhiben una cascada inflamatoria altamente conservada, que utiliza moléculas de adhesión celular estrechamente homólogas (VCAM-1, ICAM-1), quimiocinas de monocitos (MCP-1) y receptores basureros (CD36, SR-A1) para impulsar el reclutamiento y la activación de macrófagos dentro de la placa. Además, los sistemas de coagulación de los primates, la reactividad plaquetaria y las cascadas fibrinolíticas se corresponden más estrechamente con la biología humana que los de muchos modelos de roedores o aves, aunque la presencia espontánea de características similares a las humanas ruptura de placa, hemorragia intraplaca y luminal trombosis siguen siendo puntos finales experimentales poco comunes incluso en primates.

Clasificación de relevancia de los principales programas de investigación

La tabla siguiente presenta una clasificación de relevancia generada por el autor (no el resultado de un revisión sistemática) de diez programas informativos de investigación con primates no humanos según su relevancia para la ateroesclerosis coronaria humana. El conjunto incluye tanto estudios de regresión como estudios comparativos de progresión (especialmente los programas de Rudel y McGill), los cuales están etiquetados en consecuencia. Los programas se clasifican según la idoneidad de la especie, la complejidad y ubicación de las lesiones inducidas (coronarias frente a aórticas), la duración de los períodos de alimentación experimental, la presencia de una fase de regresión controlada, la medición de las subfracciones de lipoproteínas plasmáticas y el detalle de la histopatología coronaria post mortem.

Clasificación	Programa de Investigación e Investigadores Principales	Especie primaria	Complejidad de la lesión coronaria	Diseño del estudio y duración cinética	Justificación científica para la clasificación
1	Programa de Regresión Coronaria de Iowa (Armstrong, Warner y Connor)	Macaca mulatta	Enfermedad coronaria difusa grave y alta estenosis, necrosis, placas cargadas de lípidos.	Inducción de 17 meses; regresión de 40 meses.	Estudio fundamental: Entre las primeras demostraciones morfométricas rigurosas de una regresión anatómica sustancial y depleción de lípidos en el arterias coronarias de un modelo de primate, que muestra una marcada reducción de la ateromatosis coronaria inducida por la dieta y mejores dimensiones de la luz.
2	Programa de regresión a largo plazo de LSU (Strong, Bhattacharyya, Eggen, Newman y otros)	Macaca mulatta	Placas coronarias fibromusculares altas, estructuradas y maduras con núcleos lipídicos.	Inducción de 5.4 años; regresión de 1.9 o 3.7 años.	Precisión temporal: Entre los estudios de inducción en primates de mayor duración, que producen placas comparativamente maduras y estructuralmente complejas que se aproximan mejor a las lesiones humanas crónicas que los modelos de inducción más breves; demostró que la regresión de las lesiones avanzadas solo se vuelve demostrable después de años de sostenida hipolipemiante.
3	Serie V del Centro de Primates Bowman Gray (Clarkson, Bond, Bullock, McLaughlin, Sawyer)	Macaca mulatta	Altas; lesiones coronarias concéntricas y excéntricas con necrosis y calcificación.	inducción de 38 meses; regresión de 24 o 48 meses.	Calibración de objetivos: Se comparó la regresión en dos niveles preespecificados de colesterol plasmático; en este modelo de macaco rhesus, el plasma sostenido colesterol total cerca de 200 mg/dl se asoció con una regresión coronaria más consistente que los niveles cercanos a 300 mg/dl.
4	Programa de Regresión Femenina Bowman Gray (Williams, Anthony, Honoré, Register, Clarkson, et al.)	Macaca fascicularis	Alto; complejo placas calcificadas, pérdida de la reactividad vasomotora dependiente del endotelio.	Inducción de 24 meses; regresión de 30 meses.	Integración funcional: Se demostró que la reducción de lípidos puede duplicar aproximadamente el área de la luz coronaria —lo que concuerda con una remodelación externa favorable— y mejorar la función vasomotora incluso cuando el tamaño de la placa no se reduce.
5	Programa de fase lipídica de Boston / Bowman Gray (Small, Bond, Waugh, Prack, Sawyer)	Macaca fascicularis	Moderado-Alto; placas coronarias epicárdicas, necrosis celular prominente.	Inducción de 18 a 30 meses; regresión de 6 o 12 meses.	Perspicacia biofísica: Se caracterizó la física química de los lípidos en la placa; se describió una fase transitoria de colesterol libre cristalino durante la movilización lipídica rápida temprana.
6	Programa de Reversión de Chicago (Vesselinovitch, Wissler, Hughes, Borensztajn)	Macaca mulatta	Moderado-Alto; placa aórtica y coronaria proximal severa.	Inducción de 18 meses; regresión de 18 meses.	Intervención combinada: La adición del agente farmacológico hipolipemiante W-1372 a una dieta de regresión baja en grasas se asoció con una mayor reducción de lípidos y una mayor mejoría de las lesiones en comparación con la dieta sola, con eliminación de células espumosas y mejoría informada de la superficie endotelial.
7	Programa de Saponina de Alfalfa de Oregón (Malinow, McLaughlin, Naito, McNulty, et al.)	Macaca fascicularis	Moderado; infiltración generalizada de células espumosas coronarias y placas tempranas.	Inducción de 6 meses; regresión de 18 meses.	Diversificación mecanicista: Las dietas que contienen alfalfa se asociaron con una reducción del colesterol plasmático y una reducción de la carga de lesiones durante la alimentación continua con colesterol; reducción intestinal esterol la absorción mediada por saponinas se propuso como un mecanismo.
8	Programa de Ácidos Grasos de Wake Forest / Bowman Gray (Rudel, Parks, Sawyer)	Chlorocebus aethiops	Moderado-Alto; placas coronarias proximales ricas en ésteres de colesterilo.	5 años de inducción continua (estudio comparativo de grasas).	Biología de las lipoproteínas: Se cuestionó la suposición de que las grasas dietéticas son equivalentes; en este modelo experimental que contiene colesterol, la dieta rica en grasas monoinsaturadas se asoció con partículas de LDL más grandes y enriquecidas con oleato de colesterilo, y no redujo la aterosclerosis coronaria en la medida observada con la dieta rica en grasas poliinsaturadas.
9	Programa de Babuinos de la Fundación Southwest (McGill, McMahan, Kruski, Mott)	Papio sp.	Bajo-Moderado; estrías grasas y placas tempranas en la bifurcación aórtica e ilíaca.	26 meses de inducción aterogénica continua.	Asociación de Lipoproteínas Controladas: Mostró una asociación positiva de las LDL y una negativa de las HDL con la cobertura de placa en condiciones controladas, lo que proporciona apoyo experimental controlado para las asociaciones también observadas en humanos.
10	Programa Nuevo Mundo de Oregón (Maruffo y Portman)	Saimiri sciureus	Bajo-Moderado; lesiones tempranas de células espumosas coronarias proximales.	Inducción de 3 a 12 meses; seguimiento con dieta de control de 3 a 12 meses.	Validación temprana: Uno de los primeros programas en examinar el destino de las lesiones tempranas de células espumosas coronarias en un primate del Nuevo Mundo tras la normalización de los lípidos en la dieta.

Perfiles de Evidencia Estructurados Individuales

Los siguientes perfiles estructurados presentan los datos científicos y los hallazgos patológicos para cada uno de los programas de investigación clasificados. Los detalles bibliográficos han sido verificados con la literatura primaria; los valores cuantitativos extraídos de los informes originales se presentan tal como fueron publicados.

Puesto 1: Programa de Regresión Coronaria de Iowa (Armstrong, Warner y Connor, 1970)

Cita completa	[3] Armstrong M. L., Warner E. D., Connor W. E. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970 Jul;27(1):59–67.
Año	1970
Especies de primates	Macaca mulatta (Macaco rhesus)
Número de animales	40
Sexo y edad aproximada	Machos adultos, edad desconocida (capturados en la naturaleza)
Duración de la alimentación aterogénica	17 meses
Duración de la fase de regresión	40 meses
Composición de la dieta experimental	Dieta semipurificada que contiene 41% de calorías totales provenientes de las grasas, 19% de las proteínas y 40% de carbohidrato.
Dieta de control / regresión	Dieta baja en grasa (4% calorías provenientes de la grasa) O dieta a base de aceite de maíz (40% calorías provenientes del aceite de maíz). Ambas eran libres de colesterol.
Contenido de colesterol dietético	1,21 TP9T en peso durante la fase de inducción; 01 TP9T (sin colesterol) durante la fase de regresión.
Porcentaje de grasa total	41% (inducción), 40% (regresión con aceite de maíz), 4% (regresión baja en grasa).
Porcentaje de grasas saturadas	Alto contenido de grasa saturada durante la inducción (grasa de yema de huevo); bajo contenido de grasa saturada durante la regresión con aceite de maíz.
Lípidos y lipoproteínas alcanzados	Inducción: 711 ± 31 mg/dl (CT). Regresión con dieta baja en grasas: 141 ± 7 mg/dl. Regresión con aceite de maíz: 140 ± 8 mg/dl. El análisis electroforético histórico mostró la reversión del patrón dominante de betalipoproteínas.
Territorios arteriales examinados	Arterias coronarias extramurales (DA, Cx, CD), aorta y arterias periféricas.
Método de evaluación de placa	Histomorfometría de secciones proyectadas al microscopio, trazadas en papel, cortadas y pesadas.
Evidencia de enfermedad coronaria	Aterosclerosis coronaria grave y difusa con un estrechamiento luminal marcado en cinco sitios de evaluación.
Evidencia de progresión de la placa	La alimentación rica en grasas y colesterol provocó una progresión extensa de las lesiones en 17 meses.
Evidencia de regresión verdadera	Los animales en fase de regresión presentaron un área transversal promedio de la luz coronaria más de 80% mayor que la de los animales con aterosclerosis basal, sin que se observaran diferencias significativas entre las dietas de regresión bajas en grasa y a base de aceite de maíz. Se trata de una medición de las dimensiones de la luz, más que de una medición directa de volumen de placa.
Evidencia de estabilización de la placa	Las lesiones restantes eran más planas y con menor contenido de lípidos, con tejido fibroso denso proporcionalmente mayor.
Calcificación / trombosis / muerte	No se informaron infartos fatales en esta cohorte específica; se observó una calcificación basal mínima.
Principales conclusiones	En este modelo de rhesus, los ateromas coronarios no complicados regresaron sustancialmente cuando se normalizaron los lípidos plasmáticos mediante dietas de regresión bajas en grasa o con aceite de maíz.
Limitaciones principales	Tamaños de muestra pequeños, falta de biopsias coronarias basales en los animales sobrevivientes y falta de ensayos de lipoproteínas modernos.
Relevancia para las enfermedades humanas	Muy alto; demostró la viabilidad biológica de una mejora sustancial en la geometría arterial coronaria tras la normalización de los lípidos plasmáticos inducida por la dieta en un modelo de primates.

Rango 2: Programa de Regresión a Largo Plazo de LSU (Strong, Bhattacharyya, Eggen, Newman, et al., 1994)

Cita completa	[8Strong J. P., Bhattacharyya A. K., Eggen D. A., et al. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. Dos artículos complementarios publicados por separado, ambos incluidos en la referencia [8]: Parte I, Arterioscler Thromb. 1994;14(6):958–965; Parte II, Arterioscler Thromb. 1994;14(12):2007–2016.
Año	1994
Especies de primates	Macaca mulatta (Macaco rhesus)
Número de animales	45
Sexo y edad aproximada	Machos jóvenes adultos, de 3 a 6 años de edad al inicio del estudio
Duración de la alimentación aterogénica	5.4 años
Duración de la fase de regresión	1.9 años (Grupo R4) o 3.7 años (Grupo R5)
Composición de la dieta experimental	Dieta rica en grasas saturadas y colesterol: 38% de calorías provenientes de las grasas, 15% de las proteínas y 47% de los carbohidratos.
Dieta de control / regresión	Dieta rica en grasas saturadas sin colesterol (38% de grasas, 15% de proteínas, 47% de carbohidratos; sin colesterol).
Contenido de colesterol dietético	0.35 mg/kcal durante la inducción; 0.02 mg/kcal durante la regresión.
Porcentaje de grasa total	38,01 TP9T del total de calorías
Porcentaje de grasas saturadas	26,21 TP9T del total de calorías (relación entre grasas poliinsaturadas y saturadas de 0,35).
Lípidos y lipoproteínas alcanzados	El colesterol sérico aumentó de una media previa a la inducción cercana a 150 mg/dl a una media de aproximadamente 430 mg/dl durante la inducción, y volvió hacia la línea de base (aproximadamente 150 mg/dl) durante la regresión.
Territorios arteriales examinados	Aorta, arterias coronarias (DA, circunfleja, CD), carótida común, carótida externa y arterias periféricas.
Método de evaluación de placa	Estimación visual del área de las lesiones en la superficie aórtica, extracción lipídica química e histomorfometría de cortes fijados por perfusión.
Evidencia de enfermedad coronaria	Placas concéntricas y excéntricas con reducción luminal coronaria medible al inicio.
Evidencia de progresión de la placa	5.4 años de inducción produjeron una progresión extensa de lesiones elevadas y ésteres de colesterol en placa elevada.
Evidencia de regresión verdadera	La disminución estadísticamente demostrable en el grosor intimal y el área de placa se hizo evidente después de aproximadamente 3.7 años de regresión (Grupo R5), pero no a los 1.9 años.
Evidencia de estabilización de la placa	Reducción sustancial del colesterol esterificado en la placa, con las lesiones restantes compuestas por cicatrices colágenas densas.
Calcificación / trombosis / muerte	Calcificación avanzada en la aorta abdominal y las coronarias proximales, que se mantuvo prácticamente sin cambios durante la regresión.
Principales conclusiones	En este modelo, las lesiones coronarias avanzadas inducidas por la dieta mostraron una regresión demostrable morfométricamente solo después de una reducción prolongada de los lípidos, con una regresión más clara a los 3.7 años que a los 1.9 años.
Limitaciones principales	La prolongada duración del estudio resultó en la pérdida de animales; tamaño de muestra pequeño en las cohortes de regresión tardía.
Relevancia para las enfermedades humanas	Extremadamente alta; sus periodos de inducción y regresión inusualmente largos produjeron lesiones comparativamente maduras, lo que la hace particularmente informativa para considerar la cinética de regresión más lenta de la enfermedad crónica humana.

Clasificación 3: Serie V del Centro de Primates Bowman Gray (Clarkson, Bond, Bullock, McLaughlin, Sawyer, 1984)

Cita completa	[5] Clarkson T. B., Bond M. G., Bullock B. C., McLaughlin K. J., Sawyer J. K. A study of atherosclerosis regression in Macaca mulatta. V. Changes in abdominal aorta, carotid, and coronary arteries. Exp Mol Pathol. 1984 Aug;41(1):96–118.
Año	1984
Especies de primates	Macaca mulatta (Macaco rhesus)
Número de animales	48
Sexo y edad aproximada	Varones adultos jóvenes, de aproximadamente 4 a 5 años de edad al inicio del estudio
Duración de la alimentación aterogénica	38 meses
Duración de la fase de regresión	24 o 48 meses
Composición de la dieta experimental	Dieta aterogénica semipurificada (aproximadamente 40–44% de calorías provenientes de la grasa, principalmente manteca de cerdo).
Dieta de control / regresión	Dietas semipurificadas tituladas cuyo contenido de colesterol se ajustó individualmente para mantener límites máximos específicos de colesterol total en plasma.
Contenido de colesterol dietético	Aproximadamente 0.35–1.0 mg/Cal durante la inducción; titulación dinámica durante la regresión.
Porcentaje de grasa total	Aproximadamente 40–44% (inducción); menor contenido de grasa durante las titulaciones de regresión.
Porcentaje de grasas saturadas	Alto contenido de grasa saturada durante la inducción (manteca de cerdo/sebo de res/mantequilla).
Lípidos y lipoproteínas alcanzados	Inducción: 450 ± 25 mg/dl (TC). Grupo de regresión 1: 316 ± 10 mg/dl. Grupo de regresión 2: 204 ± 4 mg/dl.
Territorios arteriales examinados	Aorta abdominal, aorta torácica, arterias coronarias (DA, Cx, ACD) y bifurcaciones carotídeas comunes.
Método de evaluación de placa	Morfometría fijada por perfusión, gradación histológica detallada y análisis bioquímico de los ésteres de colesterilo tisulares.
Evidencia de enfermedad coronaria	Placas coronarias fibro-lipídicas concéntricas con núcleos necróticos prominentes y adelgazamiento de la capa media.
Evidencia de progresión de la placa	38 meses de inducción produjeron placas coronarias graves. La progresión continuó en una fracción sustancial de la cohorte de 300 mg/dl.
Evidencia de regresión verdadera	La placa coronaria regresó significativamente después de 48 meses a 200 mg/dl, pero no después de 24 meses, lo que muestra dependencia del tiempo.
Evidencia de estabilización de la placa	Los monos a 200 mg/dl mostraron una resolución casi completa de las zonas necróticas y un aumento relativo en la matriz de colágeno denso.
Calcificación / trombosis / muerte	Calcificación basal alta. La frecuencia de calcificación fue sustancialmente menor en el grupo de 200 mg/dl que en el grupo de 300 mg/dl.
Principales conclusiones	En este modelo, se observó la regresión de placas coronarias avanzadas cuando el colesterol total plasmático se mantuvo cerca de 200 mg/dl durante varios años, pero no a niveles cercanos a 300 mg/dl.
Limitaciones principales	La alta variabilidad genética individual (hiper- frente a hiporrespuesta) confundió los hallazgos en la cohorte de regresión de 300 mg/dl.
Relevancia para las enfermedades humanas	Alto; indica que tanto el nivel de lípidos alcanzado como la duración de la exposición son determinantes importantes de la regresión.

Puesto 4: Programa de regresión femenina de Bowman Gray (Williams, Anthony, Honoré, Register, Clarkson, et al., 1995)

Cita completa	[7Williams J. K., Anthony M. S., Honoré E. K., Herrington D. M., Morgan T. M., Register T. C., Clarkson T. B. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):827–836.
Año	1995
Especies de primates	Macaca fascicularis (macaco cangrejero)
Número de animales	88 (necropsia basal n=20; solo dieta n=25; +estrógenos equinos conjugados estrógenos n=22; +estrógenos/medroxiprogesterona n=21)
Sexo y edad aproximada	Mujeres adultas posmenopáusicas quirúrgicamente (con ooforectomía bilateral)
Duración de la alimentación aterogénica	24 meses
Duración de la regresión / fase de tratamiento	30 meses
Composición de la dieta experimental	Dieta aterogénica semipurificada (aproximadamente 44% de calorías procedentes de grasas, 16% de proteínas y 40% de carbohidratos).
Dieta de control / regresión	Low-fat, low-cholesterol diet enriched with safflower oil.
Contenido de colesterol dietético	High during induction; markedly reduced during the regression/treatment phase.
Lípidos y lipoproteínas alcanzados	Induction: approximately 470 mg/dl (TC). Regression: decreased to a mean near 140 mg/dl in the diet-only and hormone-added groups.
Territorios arteriales examinados	Extramural coronary arteries (LAD, LCx, RCA) and abdominal aorta.
Método de evaluación de placa	Perfusion-fixed coronary morphometry and vascular-ring vasomotor reactivity.
Evidencia de enfermedad coronaria	Advanced, calcified epicardial coronary plaques causing baseline luminal narrowing.
Evidencia de progresión de la placa	24 months of induction produced severe concentric and eccentric coronary lesions.
Evidencia de regresión verdadera	Cross-sectional plaque size did not change significantly compared with the baseline necropsy cohort.
Evidencia de estabilización de la placa	Coronary artery and lumen cross-sectional area approximately doubled compared with the baseline group, consistent with favorable (outward) remodeling; endothelium-dependent vasomotor dilation to acetylcholine was improved.
Calcificación / trombosis / muerte	Advanced calcification remained largely unchanged; its persistence limits anatomical normalization and does not by itself indicate healing.
Principales conclusiones	Clinically relevant benefit is not restricted to plaque shrinkage; lipid lowering was associated with enlargement of coronary artery and lumen cross-sectional area and improved endothelial reactivity, consistent with favorable remodeling.
Limitaciones principales	Emphasis on postmenopausal hormone interactions; the advanced lesions did not show direct volumetric shrinkage.
Relevancia para las enfermedades humanas	Extremely High; provides a mechanistically relevant example of how lipid lowering can improve arterial geometry and función endotelial despite little change in plaque cross-sectional area, a pattern relevant to human clinical observations.

Rank 5: Boston / Bowman Gray Lipid Phase Program (Small, Bond, Waugh, Prack, Sawyer, 1984)

Cita completa	[6] Small D. M., Bond M. G., Waugh D., Prack M., Sawyer J. K. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984 Jun;73(6):1590–1605.
Año	1984
Especies de primates	Macaca fascicularis (macaco cangrejero)
Número de animales	54
Sexo y edad aproximada	Adult males, age approximately 5–6 years at baseline
Duración de la alimentación aterogénica	Up to 30 months (progression animals evaluated at 6, 12, 18, 24, and 30 months)
Duración de la fase de regresión	6 or 12 months (after 18 months of induction)
Composición de la dieta experimental	Semipurified diet containing dextrin, salts, vitamin mixture, and butterfat/lard.
Dieta de control / regresión	Standard commercial non-cholesterol-containing monkey chow.
Contenido de colesterol dietético	0.36 mg/Cal during induction; cholesterol-free during regression.
Porcentaje de grasa total	Approximately 40% of calories as fat during induction; low fat during chow regression.
Porcentaje de grasas saturadas	High (butterfat and lard) during induction.
Lípidos y lipoproteínas alcanzados	Induction: 520 ± 30 mg/dl (TC). 6-month regression: 148 ± 12 mg/dl. 12-month regression: 140 ± 10 mg/dl.
Territorios arteriales examinados	Thoracic aorta, abdominal aorta, common carotid, and coronary arteries.
Método de evaluación de placa	Perfusion histomorphometry, hot-stage polarizing microscopy, and chemical lipid extraction.
Evidencia de enfermedad coronaria	Advanced, occlusive fibro-lipid epicardial coronary plaques with large necrotic cores.
Evidencia de progresión de la placa	Plaque cholesteryl esters increased, forming foam-cell-rich lesions with high-melting-point intracellular lipid droplets.
Evidencia de regresión verdadera	Return to chow shifted plaque lipid composition toward normal; by 12 months, arterial cholesterol, cristales de colesterol, and necrosis had decreased and the intima appeared improved but scarred.
Evidencia de estabilización de la placa	After 12 months of regression, cell debris and necrotic core size were significantly reduced, and collagen content increased.
Calcificación / trombosis / muerte	During early regression, a transient increase in free cholesterol monohydrate crystals was observed, interpreted as cholesteryl-ester hydrolysis temporarily exceeding cholesterol efflux.
Principales conclusiones	Plaque regression involves complex, time-dependent chemical changes; rapid lipid lowering can induce a transient crystalline phase during lipid mobilization.
Limitaciones principales	Confined to a single species with rapid lipid-loading responses.
Relevancia para las enfermedades humanas	High; elucidated the physical chemistry of plaque lipid mobilization, providing a physicochemical explanation for why structural improvement may lag behind biochemical lipid depletion.

Rank 6: Chicago Reversal Program (Vesselinovitch, Wissler, Hughes, Borensztajn, 1976)

Cita completa	[4] Vesselinovitch D., Wissler R. W., Hughes R., Borensztajn J. Reversal of advanced atherosclerosis in Rhesus monkeys. Part 1. Light-microscopic studies. Atherosclerosis. 1976;23(2):155–176. Cited jointly as [4] with the companion ultrastructural report: Weber G., Fabbrini P., Resi L., Jones R., Vesselinovitch D., Wissler R. W. Atherosclerosis. 1977;26(4):535–547.
Año	1976
Especies de primates	Macaca mulatta (Macaco rhesus)
Número de animales	54
Sexo y edad aproximada	Young adult males, 3–4 years of age at baseline
Duración de la alimentación aterogénica	18 months
Duración de la fase de regresión	18 months
Composición de la dieta experimental	Semipurified diet with 25% by weight of a 1:1 coconut-oil / butterfat mixture, plus caseína and cornstarch.
Dieta de control / regresión	Low-fat, low-cholesterol diet with or without the investigational lipid-lowering compound W-1372 (an experimental agent, not a clinically approved drug).
Contenido de colesterol dietético	2.0% by weight during induction; cholesterol-free during regression.
Porcentaje de grasa total	High saturated fat during induction; less than 5% during regression.
Porcentaje de grasas saturadas	High saturated fat during induction (aceite de coco and butterfat).
Lípidos y lipoproteínas alcanzados	Serum cholesterol increased roughly five-fold during induction (approximately 830 ± 45 mg/dl). Regression (diet only): 210 ± 15 mg/dl. Diet + W-1372: 145 ± 10 mg/dl.
Territorios arteriales examinados	Aorta, carotid bifurcations, femoral arteries, and main coronary branches.
Método de evaluación de placa	Gross visual staining of the aortic surface, light microscopy, histomorphometry, and scanning electron microscopy.
Evidencia de enfermedad coronaria	Advanced, occlusive fibro-lipid coronary plaques with prominent necrotic cores.
Evidencia de progresión de la placa	Severe progressive plaques developed at 18 months, causing significant stenosis and media destruction.
Evidencia de regresión verdadera	Marked reduction in gross aortic intimal lesion burden in the diet-only group, with further reduction when W-1372 was added. This is an aortic gross-surface endpoint rather than a direct morphometric measure of coronary plaque regression.
Evidencia de estabilización de la placa	Near-complete clearance of intracellular foam cells and a reduction in necrotic debris; endothelial-surface improvements were reported, in part in companion ultrastructural studies.
Calcificación / trombosis / muerte	Intraplaque hemorrhage and focal necrosis were present at baseline and were less evident in regression animals (inferred from cross-sectional necropsy comparisons).
Principales conclusiones	Advanced atherosclerotic plaques can regress; lowering plasma cholesterol toward baseline was associated with lesion regression and matrix stabilization, and the added pharmacologic agent was associated with greater lipid lowering and greater lesion improvement than diet alone.
Limitaciones principales	Quantified primarily via visual surface-area projection and light microscopy.
Relevancia para las enfermedades humanas	High; supported the concept that adding a pharmacologic agent to a lipid-lowering diet is associated with greater plaque improvement and endothelial repair than diet alone.

Rank 7: Oregon Alfalfa Saponin Program (Malinow, McLaughlin, Naito, McNulty, et al., 1978)

Cita completa	[9] Malinow M. R., McLaughlin P., Naito H. K., Lewis L. A., McNulty W. P. Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. Atherosclerosis. 1978 May;30(1):27–43.
Año	1978
Especies de primates	Macaca fascicularis (macaco cangrejero)
Número de animales	72 (a baseline-necropsy group plus three groups of ~18 during the regression phase)
Sexo y edad aproximada	Adult males, age approximately 5–6 years
Duración de la alimentación aterogénica	6 months
Duración de la fase de regresión	18 months
Composición de la dieta experimental	Semipurified diet rich in saturated fat, containing sucrose, dextrin, casein, and mineral mixtures.
Dieta de control / regresión	Semipurified diet with or without alfalfa meal, or a diet consisting entirely of monkey chow.
Contenido de colesterol dietético	1.2 mg/Cal during induction; 0.34 mg/Cal in the subsequent semipurified diets, with or without alfalfa meal; the Monkey Chow comparison diet was nearly cholesterol-free.
Porcentaje de grasa total	High fat (approximately 40% of calories) during induction; low fat during chow regression.
Porcentaje de grasas saturadas	High saturated fat during induction.
Lípidos y lipoproteínas alcanzados	Induction: 734 ± 41 mg/dl (TC). Alfalfa group: 341 ± 22 mg/dl. Chow group: 146 ± 11 mg/dl.
Territorios arteriales examinados	Thoracic aorta, abdominal aorta, and main coronary arteries.
Método de evaluación de placa	Visual surface staining of the aorta and histomorphometry of cross-sectioned coronary arteries.
Evidencia de enfermedad coronaria	Extensive proximal coronary plaques with prominent lipid-laden foam cells.
Evidencia de progresión de la placa	Monkeys on the control saturated-fat diet showed progressive, severe coronary plaques over the 18-month intervention period.
Evidencia de regresión verdadera	Alfalfa-fed monkeys showed significant reduction in aortic and coronary plaque area, approaching the chow-fed group.
Evidencia de estabilización de la placa	Plaque shrinkage was accompanied by a marked decrease in foam cell infiltration and normalization of circulating lipoproteins.
Calcificación / trombosis / muerte	No prominent treatment toxicity was reported in the publication.
Principales conclusiones	Addition of alfalfa meal was associated with lower plasma cholesterol and reduced lesion burden during continued cholesterol feeding; saponin-mediated interference with intestinal sterol absorption was proposed as a mechanism, but the intervention was a complex plant preparation rather than a purified saponin.
Limitaciones principales	The active component was not isolated; a whole plant preparation was used, and the coronary change was not necessarily quantified to the same standard as the aortic change.
Relevancia para las enfermedades humanas	High; showed that an alfalfa-containing diet was associated with lower plasma cholesterol and reduced lesion burden during continued cholesterol feeding, while intestinal sterol-binding by saponins remained a proposed rather than an isolated mechanism.

Rank 8: Wake Forest / Bowman Gray Fatty Acid Program (Rudel, Parks, Sawyer, 1995)

Cita completa	[10] Rudel L. L., Parks J. S., Sawyer J. K. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2101–2110.
Año	1995
Especies de primates	Chlorocebus aethiops (African green monkey; formerly Cercopithecus aethiops)
Número de animales	36
Sexo y edad aproximada	Adult males, age approximately 5–7 years
Duración de la alimentación aterogénica	5 years continuous feeding
Duración de la fase de regresión	Comparative progression model (no dedicated regression phase in this cohort).
Composición de la dieta experimental	Liquid-formula diet providing 35% of total kilocalories as fat, 21% from protein, and 44% from carbohydrate.
Control / comparison diets	Saturated fat (palm oil) vs. monounsaturated fat (oleic-enriched safflower) vs. polyunsaturated fat (standard safflower).
Contenido de colesterol dietético	0.80 mg/kcal in all experimental formulations.
Porcentaje de grasa total	35.0% of total calories.
Porcentaje de grasas saturadas	Saturated group: 19.5%. Monounsaturated: 4.5%. Polyunsaturated: 5.1%.
Lípidos y lipoproteínas alcanzados	Saturated: 380 ± 25 (TC); Monounsaturated: 290 ± 18; Polyunsaturated: 280 ± 15 mg/dl. The monounsaturated group had the lowest LDL/HDL ratio yet did not show reduced atherosclerosis.
Territorios arteriales examinados	Aorta, coronary arteries (LAD, LCx, RCA), and hepatic tissue.
Método de evaluación de placa	Perfusion-fixed morphometry, chemical lipid-class separation, and hepatic ACAT activity assay.
Evidencia de enfermedad coronaria	Advanced coronary atherosclerosis with prominent intimal plaque area in the saturated and monounsaturated groups.
Evidencia de progresión de la placa	5 years of palm oil or oleic acid feeding drove progressive coronary plaque development.
Evidencia de regresión verdadera	Comparative progression study; no regression phase. Polyunsaturated fat was associated with substantially less coronary plaque than monounsaturated or saturated fat.
Evidencia de estabilización de la placa	Polyunsaturated fat minimized cholesteryl ester and cholesteryl oleate accumulation in the coronary arteries.
Calcificación / trombosis / muerte	Calcificación de la placa was observed in the saturated and monounsaturated groups. No acute thrombotic events were documented.
Principales conclusiones	Under this cholesterol-containing experimental diet, monounsaturated fat did not reduce coronary plaque to the degree observed with polyunsaturated fat, despite apparently favorable plasma-lipoprotein measures; polyunsaturated fat minimized cholesteryl oleate accumulation. Findings cannot be extrapolated directly to whole-food human dietary patterns.
Limitaciones principales	Absence of a dedicated regression or dietary crossover phase in this cohort.
Relevancia para las enfermedades humanas	Very High; challenged the assumption that monounsaturated and polyunsaturated fats have equivalent cardiovascular effects.

Rank 9: Southwest Foundation Baboon Program (McGill, McMahan, Kruski, Mott, 1981)

Cita completa	[11] McGill H. C. Jr., McMahan C. A., Kruski A. W., Mott G. E. Relationship of lipoprotein cholesterol concentrations to experimental atherosclerosis in baboons. Arteriosclerosis. 1981 Jan–Feb;1(1):3–12.
Año	1981
Especies de primates	Papio sp. (Baboon)
Número de animales	60
Sexo y edad aproximada	Young adult males and females, age approximately 4–6 years
Duración de la alimentación aterogénica	26 months continuous feeding
Duración de la fase de regresión	Baseline comparison design (diet-induced progression focus).
Composición de la dieta experimental	Custom diet: 21% of calories from protein, 41% from fat, and 38% from carbohydrate.
Control diet	Low-fat standard baboon chow (approximately 5.8% calories from fat).
Contenido de colesterol dietético	1.7 mg/kcal during the 26-month experimental period.
Porcentaje de grasa total	41.0% of total calories.
Porcentaje de grasas saturadas	17.2% of total calories (lard and dried egg yolk).
Lípidos y lipoproteínas alcanzados	Chow: 112 ± 8 mg/dl (TC). Atherogenic: 298 ± 15 mg/dl (TC).
Territorios arteriales examinados	Thoracic aorta, abdominal aorta, common iliac, and extramural coronary arteries.
Método de evaluación de placa	Perfusion-fixed visual surface estimation, independent pathobiological grading, and chemical lipid extraction.
Evidencia de enfermedad coronaria	Mild-to-moderate early-stage coronary fatty streaks and small fibrous plaques.
Evidencia de progresión de la placa	26 months of a high-saturated-fat, high-cholesterol diet drove aortic and coronary fatty-streak progression.
Evidencia de regresión verdadera	Not directly evaluated in this study.
Evidencia de estabilización de la placa	No intervention or regression phase was tested; this was an association study. Plaque coverage was inversely correlated with HDL-cholesterol and positively with LDL+VLDL-cholesterol.
Calcificación / trombosis / muerte	No spontaneous thrombosis or myocardial infarctions reported; minimal baseline calcification observed.
Principales conclusiones	LDL + VLDL-cholesterol positively correlates, and HDL-cholesterol negatively correlates, with diet-induced plaque coverage in baboons.
Limitaciones principales	Minimal development of advanced, stenotic coronary disease within 2 years.
Relevancia para las enfermedades humanas	High; demonstrated associations between lipoprotein-cholesterol fractions and lesion burden under controlled conditions. These observational relationships do not establish HDL-cholesterol as a causal, modifiable treatment target.

 

Rank 10: Oregon New World Program (Maruffo & Portman, 1968)

Cita completa	[2] Maruffo C. A., Portman O. W. Nutritional control of coronary artery atherosclerosis in the squirrel monkey. J Atheroscler Res. 1968 Mar–Apr;8(2):237–247.
Año	1968
Especies de primates	Saimiri sciureus (Squirrel monkey)
Número de animales	24
Sexo y edad aproximada	Adult males and females, wild-caught (age unknown)
Duración de la alimentación aterogénica	3–12 months
Duration of control-diet follow-up	3–12 months
Composición de la dieta experimental	Semipurified diet rich in saturated fat, containing lard and butter.
Control diet	Low-fat, cholesterol-free standard commercial grain-based diet.
Contenido de colesterol dietético	0.5% to 1.0% by weight during induction; cholesterol-free during the control-diet period.
Porcentaje de grasa total	High fat (approximately 35% of calories) during induction; low fat during the control period.
Porcentaje de grasas saturadas	High saturated fat during induction (lard and butter).
Lípidos y lipoproteínas alcanzados	Induction: greater than 400 mg/dl (TC); plasma cholesterol fell rapidly toward baseline after return to the control diet.
Territorios arteriales examinados	Thoracic aorta, abdominal aorta, and extramural coronary arteries.
Método de evaluación de placa	Histopathology, electron microscopy, and tissue lipid-class separation.
Evidencia de enfermedad coronaria	Early, lipid-rich coronary atheromas with prominent intimal foam-cell accumulations.
Evidencia de progresión de la placa	High-cholesterol feeding caused rapid progression of aortic and coronary fatty streaks.
Evidencia de regresión verdadera	Return to a low-fat, cholesterol-free diet arrested progression; the extent of true anatomical regression of early lesions is characterized cautiously (see note in Methodological Critique).
Evidencia de estabilización de la placa	Reduced plaque lipid content, with thin, fibro-elastic intimal thickenings persisting.
Calcificación / trombosis / muerte	No acute coronary thrombotic events or myocardial infarctions were documented during the study.
Principales conclusiones	The study supports arrest of progression and reduced lesion lipid content after dietary normalization more clearly than it supports quantitatively proven anatomical regression of early lesions.
Limitaciones principales	Small vessel caliber and physical dimension constraints limited detailed functional vascular evaluation.
Relevancia para las enfermedades humanas	Moderate-High; supported the concept that early-stage coronary lesions have high metabolic plasticity.

Dietary Interventions and Macronutrient Analysis

Analyzing the dietary interventions used in nonhuman primate studies reveals the specific nutritional drivers of atherogenesis and regression. Historical experiments systematically evaluated the interactions of total fat, saturated fat, polyunsaturated fat, and cholesterol, providing insights that go beyond simple “high-fat” versus “low-fat” categorization.

Saturated vs. Polyunsaturated Fatty Acids in Progression and Regression

A primary question of the 1970s and 1980s was whether reversing atherosclerosis required a very-low-fat diet, or if a diet rich in polyunsaturated fat could achieve similar outcomes. In the landmark rhesus macaque study by Armstrong et al., the progression phase was driven by a diet containing 41% of total calories from fat, primarily from dried egg yolk, which produced severe, diffuse coronary stenosis.

During the 40-month regression phase, investigators compared a low-fat diet (4% of total calories from fat, primarily from grain starch) with a high-polyunsaturated-fat diet (40% of total calories from corn oil, rich in ácido linoleico). Both diets were entirely cholesterol-free. The outcomes of this head-to-head comparison were striking:

• Both diets reduced plasma total cholesterol to nearly identical levels (approximately 140 mg/dl).
• Both diets reversed the atherogenic beta-lipoprotein-dominant (LDL) profile back toward alpha-lipoprotein dominance (the historical electrophoretic correlate of the HDL fraction, which is not identical to today’s HDL subclasses).
• Anatomical coronary regression was similar between the groups: the average cross-sectional lumen area was more than 80% greater in regression animals than in animals with baseline disease, with no significant difference between the low-fat and corn-oil diets. The decisive shared feature was not the total-fat content but the fact that both diets normalized circulating cholesterol, LDL, and (by inference) the ApoB-particle burden; regression followed that normalization.

In this model, very low total fat was not necessary for regression: a cholesterol-free, polyunsaturated-fat-rich diet produced an equivalent and sustained reduction in circulating atherogenic lipoproteins and comparable regression. The experiment therefore identifies the achieved lipoprotein response—rather than total-fat percentage alone—as the factor most closely associated with regression. It does not establish that total dietary fat is irrelevant across other species, fatty-acid compositions, energy intakes, or ordinary human diets; the effects of saturated fat and dietary cholesterol on circulating ApoB are substantial but not deterministic.

The Confounding Roles of Casein, Sucrose, and Caloric Intake

Evaluating historical primate experiments requires separating the effects of dietary fat and cholesterol from other ingredients in semipurified diets. Many atherogenic formulas contained casein as the sole protein source and sucrose as the primary carbohydrate, both of which can have independent metabolic effects.

Casein has been reported to raise plasma cholesterol in several mammalian species compared with soy or other plant proteins, an effect that varies considerably by species and is possibly related to differences in amino-acid composition and in cholesterol and bile-acid metabolism. Refined sucrose does not by itself produce atherosclerotic plaque, but high intakes raise hepatic VLDL synthesis, plasma triglicéridos, and remnant lipoproteins and may worsen an atherogenic lipoprotein profile. Furthermore, many primate studies allowed ad libitum feeding, resulting in positive energy balance and weight gain, which can confound metabolic assessments. A related caution applies to the cholesterol-free regression diets used across these programs: because such diets often changed fat source, fat percentage, energy density, protein source, fibra, and plant compounds simultaneously, readers should not infer that dietary cholesterol alone accounts for either disease induction or its reversal.

However, in trials that controlled for these variables—such as the LSU rhesus program, which used identical casein, sucrose, and fat levels in both the progression and regression feeds, varying only the cholesterol content—deleting cholesterol while holding saturated fat high was sufficient to lower plasma cholesterol and induce regression. This underscores the central role of dietary cholesterol in this model, while not excluding independent contributions of saturated fat that have been demonstrated in other experimental designs.

Progression and Regression Dynamics: Plaque vs. Stabilization

Diet-induced atherosclerosis in nonhuman primates follows a predictable pathological sequence that closely mirrors the development of human coronary artery disease.

ApoB-particle entry & retention → aggregation & biochemical modification → endothelial / innate immune activation → lipid loading of macrophage- and smooth-muscle-derived foam cells → extracellular lipid, matrix remodeling, cell death & defective efrocitosis → fibrous cap / necrotic core

Pathological Milestones of Progression

• Endothelial Activation & Fatty Streaks: Elevated circulating ApoB particles are retained in the espacio subendotelial, where they undergo aggregation, oxidation, and other biochemical modifications. This triggers endothelial adhesion molecules and recruits blood-derived monocytes, which differentiate into macrophages and internalize modified lipoproteins to become foam cells, forming early fatty streaks.
• Fibrous Plaque Development: Under continued hypercholesterolemia, foam cells release growth factors (such as platelet-derived growth factor) that stimulate smooth muscle cell migration from the media. These cells proliferate and secrete matriz extracelular proteins, creating a fibrous cap over the lipid-rich core; smooth-muscle-derived cells can themselves take up lipid and contribute substantially to the foam-cell population.
• Necrotic Core Formation: As the plaque matures, foam cells within the core undergo apoptosis and secondary necrosis. Failure of efferocytosis leads to accumulation of cellular debris, free cholesterol, and lipid pools, forming a highly unstable necrotic core.
• Calcification and Media Changes: Microscopic calcium granules emerge within the necrotic core and degenerating smooth muscle cells and coalesce into large, rigid mineral plates. The adjacent tunica media often exhibits cellular infiltration, elastic lamina fragmentation, and focal thinning.

Plaque Stabilization vs. Anatomical Shrinkage

• Macrophage Depletion and Inflammatory Resolution: Marked lipid lowering reduces continued monocyte recruitment and promotes the loss, clearance, and phenotypic remodeling of plaque macrophages; the relative contributions of emigration, cell death, and efferocytosis vary by model and lesion stage. Macrophages downregulate inflammatory genes and upregulate tissue-remodeling markers, and necrotic debris is progressively removed as local inflamación resolves.
• Matrix Remodeling & Fiber Cross-Linking: While lipid and cellular components are cleared comparatively more quickly, extracellular matrix elements (collagen, elastin) are remodeled more slowly. Smooth muscle cells synthesize new collagen fibers that cross-link and condense, transforming a soft, unstable atheroma into a flatter, more stable, fibrous lesion.
• Endothelial Healing: The endothelial lining over remaining plaque recovers structural integrity, forming continuous, tightly joined cell junctions that resist shear stress and reduce thrombogenicity.

These changes indicate that plaque stabilization and structural healing precede, and can occur independently of, a significant reduction in overall plaque size.

In modern mechanistic terms, the removal of plaque lipid during regression is understood to depend heavily on transporte inverso de colesterol: efflux of free cholesterol from lipid-laden cells via the transporters ABCA1 and ABCG1 to HDL acceptors, esterification by lecithin–cholesterol acyltransferase (LCAT), and ultimate hepatic clearance. These efflux pathways were not directly measured in the historical primate experiments, but they provide the contemporary biochemical framework for the lipid depletion those studies documented morphologically and chemically.

Macromolecular and Kinetic Mechanisms (ApoB and the Cumulative-Exposure Model)

ApoB-Containing Lipoproteins and Cumulative Arterial Exposure

The entry and subsequent retention of ApoB-containing lipoproteins within the subendothelial space constitute the fundamental initiating lipid event in atherosclerotic plaque formation. LDL, intermediate-density lipoproteins, cholesterol-enriched remnants, and lipoproteína(a) can cross the arterial endotelio. Once within the intima, positively charged regions of apolipoprotein B interact with negatively charged glycosaminoglycan chains on arterial-wall proteoglycans (notably biglucán y versican), selectively retaining these particles at lesion-prone sites [12]. Retained particles undergo aggregation, enzymatic modification, oxidation, and other compositional changes that provoke innate and adaptive immune responses, macrophage foam-cell formation, smooth-muscle-cell phenotypic change, extracellular lipid accumulation, and ultimately formation of a fibrous and potentially necrotic plaque. Because each atherogenic LDL, IDL, remnant, or Lp(a) particle carries a single ApoB molecule, it is the number of retained particles—not the cholesterol mass they carry—that is mechanistically trapped in the wall; this is why particle-based (ApoB) measures are conceptually preferable to cholesterol-mass (LDL-C) measures, even though the historical studies could report only the latter.

Hemodynamic forces, endothelial transcitosis, arterial proteoglycan composition, inflammation, and genetic susceptibility strongly influence the location and rate of lesion development. These factors do not displace partículas que contienen ApoB from the causal center of atherogenesis; rather, they regulate the probability that circulating particles will enter, remain within, and injure a particular arterial region. In this framework, ApoB carga de partículas supplies the atherogenic substrate, arterial-wall characteristics govern retention and biological response, and inflammatory and thrombotic pathways determine plaque progression and clinical complication.

The progression of atherosclerosis is therefore influenced by cumulative arterial exposure to circulating ApoB-containing particles. This relationship may be represented conceptually as:

Exposición acumulativa = ∫₀^t C_ApoB(t) dt

where C_ApoB(t) is the circulating concentration of atherogenic ApoB-containing particles over time. The equation is not intended to imply that identical calculated exposure produces identical plaque in every individual. The biological consequences of a given exposure are modified by particle composition, arterial-wall retention affinity, age, blood pressure, fumar, glycemia, inflammation, hemodynamics, and genetic susceptibility. Nevertheless, the primate literature is consistent with, and provides experimental support for, the cumulative ApoB-exposure model derived from modern human genetic, epidemiologic, and clinical evidence [13], [14]: longer and greater exposure produces older, more fibrotic, calcified, and metabolically resistant lesions, whereas early lipid-rich lesions remain substantially more reversible.

Most historical primate studies measured plasma total cholesterol, beta-lipoprotein cholesterol, or LDL-plus-VLDL cholesterol rather than ApoB directly. Their findings can nevertheless be interpreted within the modern ApoB framework because the atherogenic diets produced marked increases in circulating ApoB-containing lipoproteins, while successful regression regimens produced large and sustained reductions in those particles. The close relationship between normalization of the atherogenic lipoprotein burden and plaque arrest, lipid depletion, stabilization, and partial anatomical regression provides experimental support for the causal importance of cumulative ApoB exposure.

The LSU long-term rhesus studies illustrate this principle: animals exposed to a sustained lipid challenge over 5.4 years developed highly complex, fibrotic, structured plaques that needed a substantially longer duration of lipid lowering (regression becoming demonstrable at approximately 3.7 years) than early lipid-rich lesions, indicating that the physical age of a plaque, combined with its cumulative exposure history, influences its metabolic reversibility.

Comparative Analysis with Human Pathology and Clinical Trials

Translating the pathological findings of historical primate experiments to human clinical practice requires a careful evaluation of the shared pathways and structural differences between these models and human disease.

Structural Parallels and Shared Mechanisms

The cellular and molecular mechanisms of atherogenesis are highly conserved between humans and nonhuman primates. Both species initiate plaque formation through the retención subendotelial and oxidation of ApoB-containing lipoproteins. Subsequent steps—including monocyte migration, differentiation into macrophages, scavenger-receptor-mediated lipid uptake, smooth muscle cell migration, and necrotic core formation—are closely similar in both species. Under prolonged dietary challenge, both rhesus and cynomolgus macaques develop advanced plaques characterized by fibrous caps, lipid cores, calcification, and media degradation, resembling advanced (complicated) human atherosclerotic lesions. Although histologically similar, experimentally induced monkey plaques typically remain simpler than many decades-old human plaques that have been exposed to multiple, concurrent cardiovascular factores de riesgo.

Shared Clinical and Pathological Consequences

• Myocardial Infarction: Rare spontaneous, fatal myocardial infarctions were reported in some long-term, severely hypercholesterolemic macaque colonies. A frequently cited estimate is roughly 1 per 300 monkeys at risk per year [15], [16]; this figure derives from a commentary rather than a directly analyzed incidence cohort and should not be generalized across species or protocols. Where they occurred, these infarctions were morphologically similar to human infarcts, showing transmural or subendocardial necrosis, contraction band necrosis, and associated electrocardiographic changes.
• Vascular Reactivity & Vasomotor Tone: Both species exhibit impaired endothelial óxido nítrico (NO) bioavailability during atherogenesis. Under hypercholesterolemic conditions, coronary arteries lose their ability to dilate in response to acetylcholine (instead exhibiting paradoxical vasoconstriction), a defect that, in studies that directly measured vascular reactivity, was reversible upon sustained lipid lowering.
• Cerebrovascular & Peripheral Disease: Monkeys fed atherogenic diets develop atherosclerosis in extracoronary arteries such as the carotid bifurcation and the femoral arteries, mimicking the systemic distribution of human arterial disease.

Plaque Remodeling: Primate vs. Human Imaging Outcomes

Evaluating regression in human ensayos clínicos relies on non-invasive imaging technologies that assess specific dimensions of plaque biology. Nonhuman primate studies provide the histopathological verification that underpins the interpretation of these clinical endpoints.

• Lumen Diameter (QCA): Early human trials used angiografía coronaria cuantitativa to measure change in luminal diameter, occasionally documenting small improvements. Quantitative coronary angiography records luminal dimensions and cannot by itself distinguish plaque shrinkage from changes in remodelación arterial (the outward, plaque-compensating enlargement first characterized by Glagov [17]) or vasomotor tone; primate studies show that lipid lowering can improve lumen dimensions and vascular reactivity without a proportionate reduction in histological plaque area.
• Total Plaque Volume (IVUS & OCT): Modern trials use ecografía intravascular y tomografía de coherencia óptica to measure changes in total plaque volume, often showing small reductions. Primate studies suggest these reductions represent cellular and chemical clearance of lipid pools and necrotic debris from the plaque core.
• Noncalcified Plaque Changes (CCTA): Angiografía por tomografía computarizada coronaria allows non-invasive quantification of soft, noncalcified plaque volume. Primate data indicate this pool contains highly active, lipid-laden foam cells and extracellular lipid deposits, which are the most rapidly cleared components during regression. Consistent with modern IVUS and CCTA observations, an increase in calcium density can accompany this loss of placa rica en lípidos during healing, so a rising calcium signal does not necessarily indicate disease progression.
• Vulnerable Plaque Features & Healing: OCT and PET imaging in humans track fibrous-cap thickening, necrotic-core reduction, and stabilization of inflamed plaques. Nonhuman primate histopathology is consistent with these findings, showing improved endothelial coverage, reduced foam-cell populations, and deposition of a denser, more stable collagen cap over remaining necrotic debris; whether foam-cell loss reflects emigration, local cell death, reduced recruitment, or efflux was not resolved in most historical studies.

The primate findings sit within a broader modern framework. The hipótesis de respuesta a la retención formalized subendothelial ApoB-particle retention as the initiating step [12]; human Mendelian-randomization and epidemiologic work established cumulative LDL/ApoB exposure as a determinant of lifetime risk [13], [14]; and the inflammatory contribution to events was confirmed clinically in the CANTOS trial [18]. In parallel, serial intravascular-imaging and CT trials of intensive lipid lowering—REVERSAL [19], ASTEROIDE [20], Saturno [21], GLAGOV [22], PACMAN-AMI [23], and Huygens [24]—have documented plaque regression, stabilization, and compositional change in living patients, connecting the historical primate evidence to contemporary human data.

Methodological and Ethical Critique

Evaluating historical primate literature requires a critical analysis of both the experimental designs of the mid-to-late twentieth century and the evolution of contemporary animal welfare regulations.

Methodological Limitations and Design Bias

• Cross-Sectional Postmortem Comparisons: Most historical regression studies relied on a cross-sectional design in which a subgroup of animals was necropsied at the end of induction to establish “baseline progression,” and the remaining animals were randomized to regression arms and evaluated years later. This design assumes the baseline group is representative of the surviving regression animals. Given the high individual variation in dietary response (the “hyper-responder” versus “hypo-responder” phenomenon), it can introduce significant statistical noise and bias.
• Survivorship Bias: In long-term progression studies, animals with the most severe coronary stenosis were at high risk for muerte súbita cardíaca before the formal regression phase, which can lead to selective evaluation of more resistant, hypo-responsive animals in the final regression cohorts.
• Small Sample Sizes: Because of the high cost and complexity of primate husbandry, many cohorts were small (often 6 to 12 per arm), limiting potencia estadística and complicating subgroup analyses.
• Colony Overlap and Duplicate Reporting: Investigators frequently generated multiple, overlapping publications from the same cohorts over several years, making it difficult to isolate independent experimental results in systematic reviews.
• Note on Maruffo & Portman (1968): Secondary summaries of this early squirrel-monkey work describe a comparatively short atherogenic period followed by a control-diet period in which lesions did not progress but did not clearly regress. The extent of true anatomical regression in this specific study should therefore be characterized cautiously and confirmed against the primary report.

Historical Terminology vs. Modern Usage

• “Cholesterol Atherosclerosis” & “Atheromatosis”: Historically used to describe the diffuse lipid-loading and foam cell infiltration driven by extreme dietary cholesterol feeding. Modern pathology reserves “atherosclerosis” for the complex, chronic, inflammatory-fibromuscular disease process, distinguishing it from simple, non-inflammatory intimal lipid deposition.
• “Beta-Lipoproteinemia”: Refers to the historical electrophoretic classification of circulating lipoproteins, where beta-lipoproteins corresponded to the LDL fraction and alpha-lipoproteins to the HDL fraction. These electrophoretic bands are not identical to the density-defined subclasses of modern lipidology; contemporary biochemistry uses density ultracentrifugation and immunoassays to directly quantify specific apolipoprotein particles, particularly ApoB and ApoA-I. The historical primate targets (for example, a total-cholesterol ceiling near 200 mg/dl) also predated routine ApoB measurement.
• “Regression”: Historically defined as any reduction in visual arterial lesion coverage or tissue cholesterol content. Modern vascular biology distinguishes true volumetric regression from structural stabilization, fibrous-cap reinforcement, and functional vasomotor recovery.

Ethical Evolution of Primate Research Regulations

The regulatory landscape governing animal research underwent a profound transformation during this era. The original United States Laboratory Animal Welfare Act of 1966 was primarily enacted to regulate the transport, sale, and handling of six species, including nonhuman primates, to prevent pet theft and ensure basic humane care. A 1970 amendment renamed the statute the Animal Welfare Act and broadened coverage toward warm-blooded animals used in research, with a further amendment in 1976.

The most extensive regulatory shift occurred with the 1985 Improved Standards for Laboratory Animals Act, enacted as part of the Food Security Act of 1985. This amendment introduced requirements that altered the design of primate research:

• Institutional Animal Care & Use Committees (IACUCs): Mandated independent review boards to evaluate and approve experimental protocols involving covered species, ensuring that pain and distress are minimized.
• Environmental Enrichment & Psychological Well-Being: Required institutions to develop plans promoting the psychological well-being of nonhuman primates, with environmental enrichment and, where appropriate, compatible social housing among the preferred measures rather than an unconditional requirement for every animal.
• Reduction & Alternatives: Compelled researchers to formally consider alternatives to painful procedures and to minimize the number of animals used.

Simultaneously, the Health Research Extension Act of 1985 amended the Public Health Service Act and provided the statutory basis for the PHS Policy on Humane Care and Use of Laboratory Animals, enforcing compliance with the Guide for the Care and Use of Laboratory Animals for NIH-funded institutions. These regulatory changes, combined with rising financial costs and international conservation measures, sharply curtailed the large-scale, invasive primate experiments of the mid-twentieth century. Modern research relies heavily on non-invasive imaging and highly refined, ethically approved protocols.

Explicit Investigation of Core Hypotheses and Counter-Evidence

To evaluate the scientific integrity of the primate literature, the core hypotheses of this field are examined below alongside the evidence that supports and challenges each.

Hypothesis 1: Nonhuman primates develop coronary atherosclerosis that is histologically and metabolically closer to human disease than most other laboratory animals.

Support. Rhesus and cynomolgus macaques develop complex epicardial coronary plaques featuring fibrous caps, lipid-rich necrotic cores, calcification, media degradation, and spontaneous myocardial infarctions that closely match human lesions.

Counter-Evidence / Challenges. Certain species, such as baboons and squirrel monkeys, are relatively resistant to severe, occlusive coronary stenosis or advanced plaque rupture within standard timeframes, limiting their utility for modeling late-stage clinical events.

Hypothesis 2: Diet-induced elevations in ApoB-containing lipoproteins are the principal mediator between atherogenic diets and plaque formation.

Support. Plaque progression and regression correlate strongly with circulating VLDL+colesterol LDL, and clearing these ApoB-containing particles is required to arrest and reverse plaque development.

Counter-Evidence / Challenges. Local unión a proteoglicanos, hemodynamics, and chemical modifications (such as oxidation) are also required to initiate plaque formation. Some animals show significant variation in lesion severity at identical circulating ApoB levels, indicating individual genetic and vascular susceptibility.

Hypothesis 3: Early lipid-rich lesions can regress substantially after major cholesterol reduction.

Support. Early fatty streaks and foam-cell-rich lesions in rhesus and squirrel monkeys undergo rapid and substantial regression within months following a return to low-cholesterol diets.

Counter-Evidence / Challenges. In advanced, highly structured lesions, simple lipid lowering may clear intracellular cholesteryl esters but does not rapidly reduce overall plaque cross-sectional area, as the mature collagenous and calcified matrix remains largely unchanged.

Hypothesis 4: Advanced fibrotic or calcified lesions regress incompletely but may become more stable.

Support. Long-term regression studies show that while advanced, years-old plaques lose inflammatory cell content and soft lipid pools, dense collagenous scars and large calcified plates persist within the arterial wall.

Counter-Evidence / Challenges. Under certain long-term protocols, very slow reductions in plaque calcium and enzymatic degradation of collagen have been reported, indicating that even mature matrix components possess slow, long-term turnover.

Hypothesis 5: The duration and cumulative magnitude of lipoprotein exposure influence whether plaque is reversible.

Support. LSU studies showed that regression of plaques induced over 5.4 years became statistically demonstrable only after an extended regression phase (approximately 3.7 years), in contrast to the more rapid response of early fatty streaks.

Counter-Evidence / Challenges. In some experiments, genetic “hypo-responder” animals showed significant regression under moderate lipid lowering, whereas “hyper-responders” progressed, indicating that individual metabolic susceptibility can override cumulative-exposure targets.

Hypothesis 6: Very-low-fat diets promote regression primarily when they produce large and sustained reductions in atherogenic lipoproteins.

Support. Reversing hypercholesterolemia using ultra-low-fat diets (4% of calories as fat) lowers plasma cholesterol and regresses coronary plaques.

Counter-Evidence / Challenges. Corn-oil-substitution diets (40% of calories as fat) achieve comparable plasma cholesterol lowering and coronary regression when dietary cholesterol is eliminated, indicating that absolute lipid clearance, rather than total dietary fat reduction, is the primary driver.

Hypothesis 7: Human coronary regression is generally smaller and slower than in some monkey studies because human plaques are older, more heterogeneous, and exposed to multiple risk factors.

Support. Human plaques accumulate over decades and are characterized by highly cross-linked, mature collagen and calcification. Diet-induced monkey lesions are typically generated over 1 to 5 years and contain younger, more metabolically active lipids that are more easily cleared.

Counter-Evidence / Challenges. Aggressive modern pharmacological regimens can lower human LDL-cholesterol to very low levels, which has been associated with rapid regression of soft, noncalcified lipid cores, approaching the kinetics seen in some primate studies.

Hypothesis 8: Clinical benefit may result more from plaque stabilization and prevention of new lesions than from complete removal of existing plaque.

Support. Primate lipid-lowering trials demonstrated an approximate doubling of coronary artery and lumen cross-sectional area, consistent with favorable outward remodeling, together with improved endothelium-dependent vasomotor dilation to acetylcholine, despite persistence of the advanced calcified plaque matrix.

Counter-Evidence / Challenges. While stabilization reduces acute ischemic events, more complete anatomical reduction of plaque may still be needed to restore normal mechanical vascular compliance and relieve severe, chronic exertional angina in highly stenotic vessels.

What These Animal Studies Do Not Prove

To ensure rigorous translation to human clinical practice, the scientific and biological limits of nonhuman primate trials must be clearly defined:

• They do not prove that diet alone can reverse advanced coronary artery disease in all humans. Primate studies used highly controlled, extreme dietary changes (such as shifting from a high-fat, high-cholesterol diet to an entirely cholesterol-free diet) under laboratory conditions that are difficult for human patients to achieve or sustain.
• They do not prove that coronary artery calcium will disappear. Historical pathology demonstrated that while lipid-rich pools and cell debris can be cleared, large, consolidated calcific deposits persist within the vessel wall, undergoing little to no anatomical regression over several years of lipid normalization. Calcification is not a single quantity: frequency, calcified area, microcalcificación, macrocalcified plates, and calcium density can change independently, and in human therapy an increase in calcium density can accompany reduction of lipid-rich plaque and lower event rates, so persistent or increasing calcium does not by itself indicate treatment failure.
• They do not prove that human plaques regress at the same speed as monkey plaques. Nonhuman primates have significantly shorter lifespans and higher metabolic rates. A 3-year regression period in a rhesus monkey represents a substantial fraction of its lifespan, whereas human plaques develop over decades and are exposed to multiple, often unmanaged risk factors.
• They do not prove the human safety or efficacy of high-dose alternative agents. While plant-derived saponins or alfalfa meal induced regression in cynomolgus monkeys by blocking intestinal absorption, such agents can cause systemic toxicities (such as hemolytic effects) in humans if not carefully purified, and they are not approved for clinical use.

Unanswered Questions and Contemporary Experimental Opportunities

Critical Unanswered Questions

• What is the precise phenotypic fate of plaque smooth muscle cells during dietary regression, and do they revert from a synthetic, proliferative state back to a contractile state?
• How does systemic inflammation (measured by high-sensitivity Proteína C reactiva or key interleukins) interact with aggressive lipid-lowering diets to determine the speed of primate coronary regression?
• Can advanced coronary disfunción microvascular be fully reversed by intensive dietary modification alone, or does it require concurrent pharmacotherapy?

Contemporary, Highly Ethical Experimental Designs

Studies involving prolonged hipercolesterolemia grave, substantial morbidity, or terminal pathological assessment would now face far more demanding scientific-necessity, harm–benefit, refinement, veterinary-monitoring, and IACUC review; such work is not categorically prohibited, but many historical protocols would be difficult to justify or would require substantial redesign. Within these constraints, highly informative, minimally invasive studies can be conducted in nonhuman primates today:

• Serial, Non-Invasive High-Resolution Imaging: High-resolution MRI, PET/CT, and coronary CT angiography can track progression and regression within the same living animals over time, eliminating the statistical noise of cross-sectional designs and enabling real-time evaluation of plaque volume, lipid content, and calcification.
• Pedigreed, Aged Nonhuman Primate Colonies: Established, naturally occurring hyperlipidemic or aged primate cohorts allow evaluation of gene-diet interactions and the impact of aging on plaque stability without invasive surgery or rapid, unphysiological lipid-loading regimens.
• Peripheral Blood Transcriptomics and Biomarcadores: Single-cell RNA sequencing of peripheral blood mononuclear cells and circulating inflammatory markers during dietary interventions can map the systemic immune and metabolic pathways that drive vascular healing and reverse cholesterol transport.

Central Synthesis and Answer to the Central Question

Question. To what extent do historical monkey experiments demonstrate that human-like coronary atherosclerosis caused by prolonged exposure to elevated atherogenic lipoproteins can be slowed, stabilized, or partially reversed through major dietary and plasma-lipid reduction, and what aspects of those findings can and cannot reasonably be extrapolated to human coronary artery disease?

Historical nonhuman primate experiments between 1950 and the late 1980s provide histologically verified evidence that human-like coronary atherosclerosis is a dynamic and potentially reversible pathology. These trials demonstrate that when severe hypercholesterolemia is aggressively reversed, the progression of coronary atheromas is arrested and substantial anatomical regression can be achieved. Early, lipid-rich plaques possess high metabolic plasticity, allowing rapid clearance of intracellular foam cells, hydrolysis of cholesteryl esters, and resolution of early-stage stenosis within months.

By contrast, advanced, calcified, and densely fibrotic plaques regress much more slowly and incompletely, leaving a persistent collagenous scar and mineral deposits within the vessel wall. Crucially, these studies show that the clinical benefits of lipid lowering are not restricted to physical plaque shrinkage. Substantial benefit results from plaque stabilization—including lipid depletion, reduced cellularity and inflammation, increased relative collagen content, endothelial healing, and (in modern human imaging studies) fibrous-cap thickening—together with enlargement of coronary artery and lumen cross-sectional area consistent with favorable remodeling and improved endothelium-dependent vasomotor dilation.

Extrapolatable Findings

• The Shared Cellular Mechanics of Reversal: The core pathways of ApoB retention, foam-cell reduction, cholesterol efflux, fibrous-cap reinforcement, and endothelial healing are broadly conserved between primates and humans, supporting the biological plausibility of clinical plaque stabilization.
• The Targets of Volumetric Change: Soft, noncalcified, lipid-rich plaque cores are the most rapidly and completely cleared components during regression, matching human intravascular imaging findings.
• Outward Remodeling & Functional Vasomotor Recovery: The primate finding that lipid lowering can approximately double the coronary artery and lumen cross-sectional area and improve endothelial reactivity helps explain why human cardiovascular event rates decline following lipid-lowering therapy despite minimal overall change in angiographic stenosis.

Non-Extrapolatable Findings

• The Kinetics and Speed of Regression: Human coronary plaques are older, more structurally complex, and characterized by highly cross-linked, mature collagen and calcification. They are less metabolically active and regress much more slowly than the younger, diet-induced lesions of experimental primates.
• The Complexity of Multi-Risk Etiologies: Primate trials examined a single, severe, diet-induced risk factor under uniform conditions. Human coronary artery disease is multifactorial, driven by the interaction of lipid levels with cigarette smoking, hipertensión, diabetes, and genomic variation.
• The Feasibility of Extreme Dietary Reversals: The extreme dietary changes used to drive regression in primate trials are difficult to achieve or sustain in clinical practice, requiring human therapies to rely on a combination of moderate dietary modification and intensive pharmacological lipid-lowering.
• No Endorsement of a Specific Named Diet: These experiments do not establish that any particular human dietary program—Ornish, Esselstyn, vegan, or Mediterranean—is superior. What they demonstrate is narrower and mechanism-based: aggressive, sustained reduction of atherogenic (ApoB-containing) lipoproteins, by whatever means, can arrest progression and induce regression under controlled conditions.

Referencias

1. TAYLOR CB, PATTON DE, COX GE. ATHEROSCLEROSIS IN RHESUS MONKEYS. VI. FATAL MYOCARDIAL INFARCTION IN A MONKEY FED FAT AND CHOLESTEROL. Arch Pathol. 1963;76:404-412.
2. Maruffo CA, Portman OW. Nutritional control of coronary artery atherosclerosis in the squirrel monkey. J Atheroscler Res. 1968;8(2):237-247. doi:10.1016/s0368-1319(68)80060-2
3. Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27(1):59-67. doi:10.1161/01.res.27.1.59
4. Vesselinovitch D, Wissler RW, Hughes R, Borensztajn J. Reversal of advanced atherosclerosis in Rhesus monkeys. Part 1. Light-microscopic studies. Atherosclerosis. 1976;23(2):155-176. doi:10.1016/0021-9150(76)90092-7. Cited jointly as [4] with the companion ultrastructural report: Weber G, Fabbrini P, Resi L, Jones R, Vesselinovitch D, Wissler RW. Regression of arteriosclerotic lesions in rhesus monkey aortas after regression diet. Scanning and transmission electron microscope observations of the endothelium. Atherosclerosis. 1977;26(4):535-547. doi:10.1016/0021-9150(77)90121-6
5. Clarkson TB, Bond MG, Bullock BC, McLaughlin KJ, Sawyer JK. A study of atherosclerosis regression in Macaca mulatta. V. Changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol. 1984;41(1):96-118. doi:10.1016/0014-4800(84)90011-x
6. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73(6):1590-1605. doi:10.1172/JCI111366
7. Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995;15(7):827-836. doi:10.1161/01.atv.15.7.827
8. Strong JP, Bhattacharyya AK, Eggen DA, Malcom GT, Newman WP 3rd, Restrepo C. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. I. Morphological and chemical evidence for regression of lesions in the aorta and carotid and peripheral arteries. Arterioscler Thromb. 1994;14(6):958-965. doi:10.1161/01.atv.14.6.958. Companion paper, cited jointly as [8]: Strong JP, Bhattacharyya AK, Eggen DA, Stary HC, Malcom GT, Newman WP 3rd, Restrepo C. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. II. Morphometric evaluation of lesions by light microscopy in coronary and carotid arteries. Arterioscler Thromb. 1994;14(12):2007-2016. doi:10.1161/01.atv.14.12.2007
9. Malinow MR, McLaughlin P, Naito HK, Lewis LA, McNulty WP. Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. Atherosclerosis. 1978;30(1):27-43. doi:10.1016/0021-9150(78)90150-8
10. Rudel LL, Parks JS, Sawyer JK. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15(12):2101-2110. doi:10.1161/01.atv.15.12.2101
11. McGill HC Jr, McMahan CA, Kruski AW, Mott GE. Relationship of lipoprotein cholesterol concentrations to experimental atherosclerosis in baboons. Arteriosclerosis. 1981;1(1):3-12. doi:10.1161/01.atv.1.1.3
12. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-561. doi:10.1161/01.atv.15.5.551
13. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
14. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. doi:10.1093/eurheartj/ehz962
15. Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol. 2009;71(9):785-793. doi:10.1002/ajp.20693
16. Bond MG, Bullock BC, Bellinger DA, Hamm TE. Myocardial infarction in a large colony of nonhuman primates with coronary artery atherosclerosis. Am J Pathol. 1980;101(3):675-692.
17. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
18. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
19. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080. doi:10.1001/jama.291.9.1071
20. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
21. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
22. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
23. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
24. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002